Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.
Overview
Matthew Rabinowitz, the executive chairman of Natera, Inc. (NASDAQ:NTRA), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($267.99); post-transaction value based on the August 3 market close ($270.36).
Details
Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale and maintains a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.
Source
Originally published at www.fool.com.